Tests amniotic tissue grafts for chronic diabetic foot ulcers
Tests amniotic tissue grafts with standard care in adults with non-healing diabetic foot ulcers.
Key facts
- Who runs it
- Tides Medical
- Where
- Boardman, Circleville, Fresno, Los Angeles, Miami, Raleigh, Salem, and Vista, United StatesSee the 9 sites
- Trial code
- Registry title
- Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers
- Status
- Recruiting
- People taking part
- 240 people, planned
- Started
- 14 Nov 2024
- Expected to end
- 18 Nov 2026
- Type of study
- Interventional, 4 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Allograft
- Record updated
- 10 February 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a chronic, non-healing diabetic foot ulcer (Wagner Grade 1) that has been present for more than 4 weeks and less than 1 year.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Diabetic foot ulcer, Wagner Grade 1, below the medial aspect of the malleolus; ulcer size 1.0 cm2 to 25 cm2; present for more than 4 weeks and less than 1 year; adequate blood flow to the foot.
- Earlier treatment
- The ulcer must have been offloaded for at least 14 days before the treatment visit. No immune-suppressing drugs for more than two weeks, no investigational drugs or devices within 30 days, and no radiation at the ulcer site.
- Biomarker or test result
- Adequate blood flow in the affected foot shown by one of the accepted tests: TCOM or SPP of 30 mmHg or more, ABI between 0.7 and 1.3, biphasic Doppler ultrasound, or TBI above 0.6. HbA1c must not be above 12.0.
Main reasons for not taking part
- Ulcer is infected or suspicious for cancer
- Bone infection (osteomyelitis) of the affected foot
- Previous diagnosis of HIV or Hepatitis C
- Pregnant or breast-feeding
- End stage renal disease (serum creatinine 3.0 mg/dL (265 µmol/L) or more)
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Potential subjects are required to meet all of the following criteria for enrollment into the study
- At least 18 years old, inclusive
- Presence of a DFU, Wagner Grade 1, extending through the dermis provided it is below the medial aspect of the malleolus
- The index ulcer (ulcer to be evaluated in the study) will be the largest ulcer if two or more DFUs are present with the same Wagner grade and will be the only one evaluated in the study. If other ulcerations are present on the same foot, they must be more than 2 cm distant from the index ulcer
- Index ulcer has been present for greater than 4 weeks prior to SV1 and less than 1 year, as of the date the subject consents for study
- Index ulcer is a minimum of 1.0 cm2 and a maximum of 25 cm2 at SV1 and TV1
- Within 3 months of SV1, adequate circulation to the affected foot as documented by a dorsal transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 30 mmHg, or an Ankle Branchial Index (ABI) between 0.7 and 1.3 using the affected study extremity. As an alternative, arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle or a TBI (Toe Brachial Index) of > 0.6 is acceptable
- The target ulcer has been offloaded for at least 14 days, prior to TV1
- Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers or abstinence) during the course of the study and undergo pregnancy tests
- Subject understands and is willing to participate in the clinical study and can comply with weekly visits
- Subjects must have read and signed the IRB approved ICF before screening procedures are performed
Who cannot take part
- Subjects with a history of more than two weeks of treatment with immune-suppressants (including systemic corticosteroids >10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within 1-month prior to first SV1, or who receive such medications during the screening period or who are anticipated to require such medications during the course of the study
- Subjects on any investigational drug(s), Investigational products, or therapeutic device(s) within 30 days preceding SV1
- Index ulcer has been previously treated or will need to be treated with any prohibited therapies
- Subjects with a previous diagnosis of HIV or Hepatitis C
- Osteomyelitis or bone infection of the affected foot as verified by x-ray within 30 days prior to the first screening visit. (In the event of an ambiguous diagnosis, the Principal Investigator will make the final decision)
- Index ulcer(s) deemed by the investigator to be caused by a medical condition other than diabetes
- Index ulcer, in the opinion of the investigator, is suspicious for cancer and should undergo an ulcer biopsy to rule out a carcinoma of the ulcer
- Index ulcer is infected
- History of radiation at the ulcer site (regardless of time since last radiation treatment)
- Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence with medical treatment
- Index ulcer that has reduced in area by 30% or more after 14 days of SOC from SV1 to the TV1/Randomization visit
- Presence of diabetes with poor metabolic control as documented with an HbA1c >12.0 within last 90 days
- Subjects with end stage renal disease as evidenced by a serum creatinine ≥3.0 mg/dL within 6 months of enrollment
- Potential subjects meeting any of the following criteria will be excluded from enrollment and subsequent treatment
- Subject is pregnant or breast-feeding
- Presence of acute Charcot Neuroarthropathy to the affected limb
Where in United States
- Lower Extremity Institute of Research and TherapyBoardman, United StatesContact: Sara ChaszeykaTaking people
- Brock Liden DPMCircleville, United StatesContact: Rhonda QueenTaking people
- Limb Preservation Platform IncFresno, United StatesContact: Destiny BlackstoneTaking people
- Angel City ResearchLos Angeles, United StatesContact: Joanna CuevasTaking people
- Clemente Clinical ResearchLos Angeles, United StatesContact: Ernestina UribeTaking people
- Clever Medical ResearchMiami, United StatesContact: Margarita HernandezTaking people
- Foot and Ankle Specialists of the Mid-AtlanticRaleigh, United StatesContact: Allison DentonTaking people
- Foot and Ankle Specialists of the Mid-AtlanticSalem, United StatesContact: Kristie CooperTaking people
- ILD Research CenterVista, United StatesContact: Eric MartinezTaking people
About the trial
What the trial wants to find out
The purpose of this clinical investigation is to evaluate the safety and efficacy of Amnion/Chorion/Amnion allograft , Amnion/Chorion allograft, and/or Amnion/Amnion allograft, plus Standard of Care (SOC) each versus SOC alone in the treatment of chronic non-healing diabetic foot ulcers (DFU) after 12 weeks of treatment.
The 4 groups in the trial
- "Amnion/Chorion/Amnion" common/general allograft configurationTreatment being tested
Topical application of placental allograft on to surface of open chronic diabetic foot ulcer using a tri-layer dehydrated amniotic membrane allograft for the treatment of DFUs. Human amniotic membrane is a thin collagenous membrane derived from the submucosa of the placenta, the organ that connects the developing fetus to the mother's uterus. A human amniotic membrane consists of multiple layers including epithelial cells, a basement membrane, and a stromal matrix which provides a natural scaffold that allows cellular attachment or infiltration and growth factor storage.
Treatment: Allograft
- Standard of CareNo study treatment, for comparison
Standard of Care (SOC) for open chronic diabetic foot ulcer using a calcium alginate dressing and will have a silicone non-adherent dressing (MepitelTM or equivalent), a padded 3-layer dressing comprised of 4x4 gauze pads, soft roll, compressive wrap and Coban (Threeflex 3-layer or equivalent) applied. Offloading of the DFU (removable offloading boot or total contact casting \[TCC\] if the subject's foot is too large for a removable offloading boot), appropriate sharp or surgical debridement, and infection management. Graft provides a protective cover and supports the body's wound healing processes. This allograft is supplied sterile and not intended to be removed.
- "Amnion/Chorion" common/general allograft configurationOther group
Topical application of placental allograft on to surface of open chronic diabetic foot ulcer using a dehydrated human amniotic membrane allograft comprised of a tri-layer membrane (amnion/intermediate layer/chorion) which provides a natural scaffold that allows cellular attachment and infiltration. Human amniotic membrane is a thin collagenous membrane derived from the submucosa of the placenta. A human amniotic membrane consists of multiple layers including epithelial cells, a basement membrane, and a stromal matrix. Graft provides a protective cover and supports the body's wound healing processes. This allograft is supplied sterile and not intended to be removed.
Treatment: Allograft
- "Amnion/Amnion" common/general allograft configurationOther group
Topical application of placental allograft on to surface of open chronic diabetic foot ulcer using a dual layer dehydrated human amniotic membrane allograft. Human amniotic membrane is a thin collagenous membrane derived from the submucosa of the placenta, the organ that connects the developing fetus to the mother's uterus. A human amniotic membrane consists of multiple layers including epithelial cells, a basement membrane, and a stromal matrix which provides a natural scaffold that allows cellular attachment or infiltration and growth factor storage. This allograft provides a protective cover and supports the body's wound healing process. This allograft is supplied sterile and not intended to be removed.
Treatment: Allograft
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-Center, Randomized Controlled Clinical Investigation Evaluating an Amnion/Chorion/Amnion Allograft, Amnion/Chorion Allograft, And/or an Amnion/Amnion Allograft Versus Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers
- Plain-language title
- Tests amniotic tissue grafts for chronic diabetic foot ulcersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 10 February 2025